Telomir Pharmaceuticals said that new preclinical data for its lead drug candidate, Telomir-1, show it can reverse several hallmarks of cellular decline in human cell lines. According to the company, the compound improved mitochondrial function, reduced oxidative stress and restored calcium balance in stressed cells.
The company said that Telomir-1 also protected cells from metal-induced toxicity (such as iron and copper) and maintained viability under stress conditions.
These results are described by the company as supporting its research initiatives in indications such as autism spectrum disorder, spasmodic dysphonia and other degenerative or age-related disorders.
Telomir said it is advancing its longevity and regenerative-medicine platform and plans to move Telomir-1 toward human trials. The company expects to file an Investigational New Drug (IND) application and begin first-in-human dosing in the first half of 2026.
While the data are preclinical and laboratory-based, the company claims the findings represent a mechanistic foundation for broader therapeutic exploration.
